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Identity 
Other names: Cutaneous melanoma; Melanoma skin 
cancer 
Classification 
Note: Skin melanoma is a relatively common human 
cancer with an increasing incidence trend and 
originates from skin melanocytes, which are neural 
crest derived cells. Melanoma arises in more than 95%
of cases in the skin, although other sites of primary 
extracutaneous melanoma include uvea, oral and 
genital mucosae, gastrointestinal and genitourinary 
tracts, leptomeninges and lymph nodes. 
Clinics and pathology 
Embryonic origin 
Neural crest cells (this embryonic origin is valid for all 
forms of melanoma, except for uveal melanoma, which 
derives from neuroectodermal cells. 
Etiology 
A wide spectrum of risk factors for skin melanoma has 
been unravelled in the last decades. They are classi ally 
distinguished in 'host' and environmental factors. The 
strongest 'host' conditions are positive family history 
for melanoma (especially in first-degree relatives and 
in a number of 3 or more), multiple benign (often more 
than 100) or atypical nevi (the so-called 'dysplastic 
nevus syndrome'), and a previous melanoma. The first 
two risk factors may coexist in the same pedigree, thus 
delineating the Familial Atypical Mole - Multiple 
Melanoma syndrome (or FAMMM syndrome). Among 
these families, 30-40% of them display mutations in the 
CDKN2A gene, while a few kindreds are mutated in 
CDK4. Other 'host' factors that may increase the risk of 
developing melanoma are previous non-melanoma skin 
cancer and immunosuppression (such as, transplant 
recipients or patients with AIDS). 
However, solar UVR exposure remains the leading 
cause for developing skin melanoma. In fact, skin 
melanoma is strikingly more common in patients with 
type I skin, freckling, blue eyes and red hair. This 
evidence demonstrates that 'host' and environmental 
risk factors cooperate in determining the onset and
evolution of skin melanoma (this interaction has been 
recently demonstrated at the molecular level. In fact, 
ultraviolet exposure stimulates tanning in part inducing 
the action of the alpha-melanocyte-stimulating 
hormone (POMC) on the melanocortin receptor 1 - 
MC1R. Light-skinned and readheaded people carry 
specific MC1R polymorphisms that reduce its activity). 
Accumulated evidences support that intermittent sun
exposure is a major determinant for melanoma in 
contrast with cumulative sun exposure, as well as a 
history of blistering sunburn, especially in young a e 
(i.e. three or more episodes before 20 years). The risk 
related to non-solar UVR exposure is still debated. 
Epidemiology 
Melanoma is the fifth most common cancer in men and 
the sixth in women (note that this ranking may slightly 
vary among distinct populations and different 
epidemiological studies). It accounts for nearly 4%of 
all dermatologic cancers, but represents the major c use 
of death for skin cancer. The overall incidence of 
melanoma ranges from 10 to 42 new cases for 100.000 
per year. This apparent wide variability may essentially 
relay on the ethnic background of the population 
studied. The incidence of melanoma is rising by 3-8% 
per year in most people of European origin. Melanoma 
affects young and middle aged people, with a median 
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age at diagnosis of 57 years. The cancer incidence 
increase progressively after the age of 15 years until the 
age of 50 and then slows, especially in females, who
are slightly less affected than men (males are 
approximately 1.5 times more likely to develop 
melanoma than females). Nearly half of the patients 
have an age comprised from 35 and 65 years at 
diagnosis. 
Clinics 
Melanoma should be considered for every suspicious 
pigmented skin lesions. There are specific 
characteristics to be taken into account for identifyi g 
suspicious lesions which request further investigations. 
The acronym ABCDE summarizes five cardinal 
features, including:  
(i) Asymmetry; 
(ii) Border irregularity; 
(iii) Color variation; 
(iv) Diameter above 6 mm; and 
(v) Evolving, which encompasses any significant 
change in size, shape, surface, shades of color or 
symptoms (such as, itching). 
Clinical suspicion must be supported by assistive 
optical devices, such as dermatoscopes, epiluminesce t 
microscopes and/or other portable scanning units usng 
visible, infrared and UV sources. However, a firm 
diagnosis is reached only by excision and histologic 
examination. 
Pathology 
Pathologic staging of skin melanoma is crucial for 
prognosis definition and management planning. The 
Clark's model identifies 5 steps in the progression fr m 
benign nevus and metastatic melanoma:  
step 1: benign nevus; 
step 2: dysplastic nevus; 
step 3: radial-growth phase melanoma; 
step 4: vertical-growth phase melanoma; 
step 5: metastatic melanoma. 
This model also denotes qualitative anatomic levels of 
invasion:  
In level I melanoma, all tumor cells are above the 
basement membrane (malignant melanoma in situ). 
Level II melanoma invades into the papillary dermis. 
Level III melanoma fills and expands the papillary 
dermis. 
Level IV melanoma invades the reticular dermis, while 
level V melanoma reaches the subcutaneous adipose 
tissue. 
Actually, for the T staging of melanoma the primary 
determinant is the Breslow's technique, that provides a 
quantitative measurement of the depth of invasion by 
measuring the tumor thickness with an ocular 
micrometer (in millimeters). 
T1 melanomas are = 1.0 mm in thickness, 
T2 between 1.01 and 2.00 mm, 
T3 between 2.01 and 4.00 mm, and 
T4 above 4.0 mm. 
To date, the Clark's level system is the primary 
prognostic method only for T1 melanomas. 
The melanoma clinical staging include four stages. 
Stage I melanomas are those with thickness that are 1 
mm or less with no evidence of metastases. 
Stage II melanoma is diagnosed in patients with thicker 
cancers without evidence of metastases. 
Stage III melanomas are those with regional lymph 
nodes and/or an in-transit or satellite metastasis. 
Stage IV cancer is diagnosed when the melanoma 
spreads to distant sites. 
Specific determinants define the N and M axes for 
stage III and IV melanomas. 
There are unusual variants of melanoma (for which the 
standard prognostic factors should be taken into 
account), that must be differentiated form epithelial or 
mesenchymal neoplasms. 
These variants include: desmoplastic melanoma, 
mucosal melanoma, malignant blue nevus, nevoid 
melanoma, minimal deviation melanoma, small cell 
melanoma, spitzoid melanoma, dermal melanoma, 
amelanotic melanoma, myxoid melanoma, signet ring 
melanoma, balloon cell melanoma, rhabdoid 
melanoma, pigment-synthesizing animal melanoma, 
osteoid melanoma, chondroid and cartilagineous 
melanoma, and basomelanocytic tumor. 
Treatment 
After histologic diagnosis of melanoma, the first step is 
the extent of excision. The radius of this excision 
depends on the tumor thickness (Breslow's technique). 
Sentinel lymph node biopsy is requested in melanomas 
of Stage I. 
In melanomas with thickness above 2 mm, elective 
lymph node dissection is also recommended. Surgical 
excision could be considered also for local recurrences, 
in-transit metastases, regional metastases and in 
patients with metastatic disease. 
In stage III patients, the eradication of clinical 
undetectable micrometastases at the time of diagnosis 
may be obtained using adjuvant therapy, including 
interferon-alpha and ganulocyte-macrophage colony-
stimulating factor. 
In stage IV cancers the systemic therapy is based on 
decarbazide, interleukin-2, in isolation or in 
combination with other chemotherapeutic agents. 
Novel therapeutic regimens include cancer vaccines, 
angiogenesis inhibitors and novel cytotoxic agents. 
Evolution 
Usually, skin melanomas show two distinct phases of 
local invasion:  
(i) the radial-growth phase, during which tumor cells 
acquire the ability to proliferate intraepidermally; 
(ii) the vertical-growth phase, which is characteriz d by 
tumor invasion of the dermis in form of an expansile 
nodule. 
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Local invasive melanomas may reach distant skin areas 
and subcutis. The invasion of lymph vessels leads to 
lymph node metastases. 
Finally, metastatic melanomas may metastasize to 
lungs, liver, central nervous system and other organs. 
Prognosis 
The prognosis (i.e. % of 10-year survival rate) is 
directly related to the Pathologic stage. This range from 
100% for melanoma in situ to less than 6% for patients 
with a stage IV melanoma with distant metastases. 
Cytogenetics 
Cytogenetics morphological 
Numerical and structural changes visible by standard 
cytogenetics are common in sporadic melanoma, which 
is frequently aneuploid with a modal chromosomal set 
usually ranging from 24 to more than 100. 
The most common abnormality involves chromosome 1 
with deletions and translocations usually including the 
region 1p12-22. A recurrent t(1;19) translocation has 
been also described in a subset of sporadic melanoms. 
Deletions or translocations involving the long arm of 
one or both chromosome 6, commonly affecting the 
6q16-23 region, are observed in nearly 80% of skin 
melanomas. The 6 chromosome short arm is generally 
retained in form of an isochromosome (i6p). The gain 
of the short arm of chromosome 6 may have a role in 
cancer progression, especially for metastastic evolution 
(in fact, the NEDD9 gene, whose overexpression in 
associated to metastatic melanomas, maps in 6p25-
p24). 
An equally common alteration is the gain of copies of 
chromosome 7. This finding is usually associated with 
late stages of skin melanoma. 
A second set of chromosome abnormalities includes 
alterations of chromosome 2, 3, 9, 10 and 11. Among 
them, a recurrent site of alterations (predominantly 
deletions) in both premalignant nevi and metastatic 
melanomas is the short arm of chromosome 9, 
particularly the region 9q21. Loss of chromosome 10, 
especially involving the region 10q24-26, seems to be 
implicated in both the early and late stages of 
melanocytic neoplasia. In late stage melanomas, 
chromosome 10 loss often accompanies chromosome 7 
gain. At the standard cytogenetic level, the rate of 
involvement of other chromosomes (i.e. 2, 3 and 11) is 
less consistent. 
Cytogenetics molecular  
A large number of studies have searched for loss of 
heterozygosity (LOH), homozygous deletions (HD) and
amplifications in cutaneous melanomas, events that are 
difficult or impossible to identify at the standard 
cytogenetic level. 
Over the years, the improvement of laboratory 
techniques has collected a wide range of different 
approaches, including fluorescent in situ hybridization, 
standard microsatellite analysis on specific genomic 
regions and conventional chromosome-based 
comparative genomic hybridization array. Actually, the 
most sensitive technique is the high-density whole-
genome single nucleotide polymorphism array, which 
is able to detect variations in number of copies of 
genomic DNA within an interval of only 9 kb. 
Therefore, the results of this type of analysis is by far 
the most sensitive among all available approaches. 
Overall, whole chromosome arm LOH is most common 
on 9p, 9q, 10p and 10q, occurring in 40-50% of the 
cases. Considering focal (i.e. small portion of 
chromosome arms) LOH, these chromosome regions 
are involved in 49-72% of the cases. Over 40% of 
analyzed melanomas show LOH on 6q, 11q and 17p, 
while 33% on 5q. A broad spectrum of HD has been 
also registered and involves regions containing both 
well known melanoma progression associated genes 
(such as, CDKN2A and PTEN - for more details, see 
'Genes Involved and Proteins' section), and other genes, 
whose role in cancer evolution awaits further 
elucidations. In more that one fourth (25%) of 
melanomas there are chromosome gains involving 7p, 
20q and 22q. Amplifications of single genes may be 
also detected by this technique, but these data will be 
discussed in the next section. The 8q region, in which 
maps the C-MYC gene, is amplified in nearly 14% of 
the cases. 
Genes involved and Proteins 
Note: Several genes have been discovered as involved 
in the progression of cutaneous melanoma. Two major 
groups of genes have been identified: tumor suppresso  
genes and proto-oncogenes. In order to describe 
melanoma progression implicated genes, the present 
section follows this classification. In addition to those 
here described, other genes, such as NF1, NF2, TTC4, 
NME2, CDKN1A, and RAB8A, have been 
sporadically studied in melanomas, but the present data
are still very limited and not completely conclusive. 
Note: Tumor suppressor genes: 
B2M 
Location: 15q21.1 
Note: Escape by melanoma cells from T cell 
recognition through a complete lack of HLA class I 
antigen can be ascribed to beta-2-microglobulin 
(encoded by the B2M gene) aberrations. The 
combination of LOH and somatic mutation leading to a 




Note: This genes maps in a chromosome region (i.e. 
1q36) frequently deleted in melanoma. However, 
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mutations in this gene are rare and the role of this gene 
in tumor progression is probably very limited. 
CDKN2A 
Location: 9p21 
Note: The CDKN2A locus shows LOH in nearly 50% 
of melanomas, while point mutations of this gene ar 
extremely rare, probably because other mechanisms are 
involved in its inactivation (such as promoter 
methylation or homozygous deletion). 
CDKN2B 
Location: 9q21 
Note: CDKN2B maps nearly to CDKN2A and shares 
with this gene an high sequence homology. Although 
CDKN2B maps in a commonly deleted region in 
melanoma, the frequency of point mutations is 
relatively low and the actual knowledge about the rol  
of this gene in melanoma progression is limited. 
MEN1 
Location: 11q13 
Note: Mutations in menin, the gene responsible for the 
multiple endocrine neoplasia type I (MEN1), results 
mutated in nearly 1% of the analyzed melanomas. 
PTEN 
Location: 10q23.31 
Note: The chromosome region in which this gene maps 
is deleted in about 30-50% of melanomas, while 
somatic PTEN mutations have been identified in 




Note: Although the implications of CDKN2A and 
CDK4 (see below) is crucial in melanoma progression, 
the actual rate of mutations or rearrangement involving 
this gene, which is implicated in the same pathway, is 
extremely rare and confined to sporadic cases. 
TFAP2A 
Location: 6p24 
Note: Loss of AP2-alpha (the protein encoded by 
TFAP2A) expression is a crucial event in the 
melanoma development. However, the frequency of 
TFAP2A somatic mutations in melanomas is extremely 
low, thus suggesting that the AP2-alpha 




Note: TP53 mutations in melanomas are rare, occurring 
in 0-24% (mean 7%) of the analyzed tumors. However, 
UVR is very likely the cause of these mutations, as 
well as in other non-melanocytic skin tumors. 
Wnt signalling pathway tumor 
suppressor genes. 
Location: Variable (see text). 
Note: The involvement of this pathway in melanoma 
progression is clearly demonstrated by the 
overexpression of beta-catenin in nearly 30% of the 
cases. Several genes coding for proteins implicated in 
the modulation of this pathway has been studied for 
somatic mutations in relation with melanoma. Among 
them, the most frequently somatically mutated gene is 
LKB1 (i.e. the gene responsible of Peutz-Jeghers 
syndrome ; location: 19p13.3) with an overall mutation 
frequency in melanoma of 4%. Other related genes, 
namely PPP2R1A (location: 19q13.4), APC (whose 
germline mutations are associated with the familial 
adenomatous polyposis; location: 5q21-q22) and ICAT 





Note: The primary role of the protein encoded by 
CDK4 is to inactivate pRB. Mutations that 
constitutively activate the kinase, in particular those 
involving the K22 and R24 aminoacid residues, have 
been identified in a variable proportion, ranging from 
1/60 to 5/48, of the cases. 
CTNNB1 
Location: 3p22-p21.3 
Note: This gene encodes for beta-catenin. As this 
protein is overexpressed in about one third of the cases, 
several studies investigated the presence of somatic 
mutations in this gene. The overall frequency of 
CTNNB1 somatic mutations in melanoma is 2-5%. 
MAPK signalling pathway proto-
oncogenes. 
Location: Variable (see text). 
Note: This pathway may be simplified as follows. The 
growth factor receptor interaction with its ligand 
induces the activation of RAS. Its activation stimulates 
phosphorylation of RAF proteins (including BRAF), 
that in turn activate MEK1 and MEK2. The final step 
of this cascade is the transcription factors activation by 
ERK 1 and ERK 2, which are phosphorilated by MEK 
proteins. 
BRAF (location: 7q34) mutations have been identified 
in more than 60% of melanomas and approximately 
80% of these mutations occur at a single site, leading to 
the substitution of valine at position 600 with glutamic  
acid (V600E). This change mimics phosphorylation 
within the activation segment and results in constitutive 
activation of BRAF. The frequency of BRAF mutations 
in melanocytic nevi is similar to that in melanomas, 
suggesting that BRAF function perturbation is an early 
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event in melanoma development and is not sufficient to 
determine the neoplastic switch. The rate of BRAF 
mutation varies among melanoma subtypes and is 
highest in nodular melanoma and superficial spreading 
melanoma. BRAF mutations appear to be less common 
in sun-exposed areas. BRAF mutations are mutually 
exclusive to those occurring in the NRAS gene 
(1p13.2). The most common sites of mutation in this
gene are codon 12, 13, 18 and 61. 
In contrast to BRAF mutations, NRAS alterations are
more common in sun-exposed areas. This fact suggests 
that NRAS mutations may arise as a result of UVR-
induced mutagenesis. 
HRAS (location: 11p15.5) mutations are less 
commonly observed and occurs in no more than 1.5-
3% of melanomas. 
Activating changes in KRAS2 (location: 12p12.1) have 
been observed in rare cases and often associate with 
mutations in other RAS genes (i.e. NRAS and HRAS). 
Therefore, KRAS2 in a not powerful oncogene in 
melanoma progression. 
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